Form 4: Axogen Director Paul Thomas Receives Annual Equity Grant Valued at $200,000

Axogen, Inc. Director Paul Thomas was granted 18,867 Restricted Stock Units (RSUs) as part of his annual equity compensation, valued at $200,000, which will vest on June 19, 2026.

Summary

• Paul Thomas, a Director of Axogen, Inc. (AXGN), received an annual equity grant.
• The grant consists of 18,867 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was June 19, 2025.
• Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.
• The number of shares granted is based on a $200,000 valuation as of the grant date.
• These RSUs are scheduled to vest on June 19, 2026, which is the one-year anniversary of the grant date.
• Following this transaction, Paul Thomas beneficially owns 18,867 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a routine, expected compensation event that aligns director interests with shareholders, without any negative implications or surprises.

Positives

• The equity grant aligns the director's interests with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• It represents a standard practice of compensating board members with equity, which can foster long-term commitment and strategic oversight.

Future Outlook

The granted Restricted Stock Units are scheduled to vest on June 19, 2026, indicating a future milestone for the compensation to become fully owned shares.

Industry Context

The granting of Restricted Stock Units to directors is a common practice across various industries, serving as a key component of executive and board compensation packages to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as Restricted Stock Units, is a widely accepted and standard corporate governance practice across publicly traded companies in the healthcare and biotechnology sectors, similar to companies like Stryker Corporation or Medtronic plc, which also utilize equity-based compensation for their board members.
• The one-year vesting period for annual director grants is also a common structure, aiming to retain directors and ensure their continued commitment over the short to medium term.

Corporate Governance

Related Party Transactions

• The grant of Restricted Stock Units to Paul Thomas, a Director of Axogen, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The 18,867 Restricted Stock Units granted to Paul Thomas are expected to vest on June 19, 2026, at which point they will convert into shares of Axogen, Inc. common stock.

Key Dates

Keywords

Axogen, AXGN, Restricted Stock Units, RSU, Equity Grant, Director Compensation, SEC Form 4, Insider Transaction, Corporate Governance